AVTX enters the week with one of the most extreme short positioning profiles in small-cap biotech — yet the borrow market tells a notably different story from what the headline short interest figure implies.
Three-quarters of Avalo Therapeutics' free float is sold short. At 74.4% of float, short interest is not just elevated — it is deeply exceptional, ranking in roughly the 4th percentile of the ORTEX short score universe (a short score of 78.8 means 78.8% of stocks have a lower short interest burden). That figure has also been building: short interest rose 3% week-on-week to 13.49 million shares. The ORTEX short score climbed to 78.8 from 74.3 ten sessions ago, a steady drift higher that suggests shorts are not unwinding.
The borrow market complicates the simple "crowded short" narrative, however. Availability — the ratio of shares still available to borrow versus shares already lent out — is running at 182%, a level that sits in the normal-to-tight range rather than the extreme end. That's down roughly 13% on the week as demand has picked up, but it remains well above the 52-week low of 6.5%, which was the point of genuine squeeze pressure. Cost to borrow has also moved — up 26% week-on-week to 0.65% — but that absolute level is still cheap. Shorts are not being forced out by economics here; they're paying almost nothing to maintain their positions. Options positioning is equally subdued: the put/call ratio of 0.53 sits essentially at its 20-day average with a z-score barely above zero, suggesting options traders are not loading up on downside protection or aggressively chasing calls. Overall, the positioning picture is one of deeply entrenched short interest, but without the borrow-market tightness that typically catalyses a forced unwind.
The Street is meaningfully more constructive than short sellers. All 12 analysts tracked carry Buy-equivalent ratings, with a mean price target around $44 — more than 2.6x the current price of $16.51. The most recent moves, from Guggenheim and HC Wainwright in early August, were modest target trims (to $48 and $30, respectively) while both maintained Buy ratings, consistent with post-earnings recalibrations rather than conviction changes. B of A Securities and Leerink Partners both initiated with Buy/Outperform ratings in the summer, adding to the bullish chorus. The bull case centres on abdakibart, Avalo's anti-IL-1β antibody targeting hidradenitis suppurativa, and the Phase II LOTUS study results that showed a promising efficacy profile. Bears flag pipeline concentration risk — the company is essentially a one-asset bet — and point to financial stress metrics: a Piotroski F-score of 1, deeply negative return on assets, and an EPS yield of -16.6%. The stock's EPS surprise factor score ranks in the 81st percentile, indicating it has beaten depressed estimates consistently, but that alone doesn't resolve the cash-burn question ahead of a Phase III programme.
Institutional activity tells a story of active hands building positions this year. BlackRock added more than 4 million shares in the period through August, now holding 8.1% of the company. State Street built a near-entirely new position, accumulating 2.8 million shares. Deep Track Capital, TCG Crossover, and Commodore Capital all disclosed new stakes above 5% in filings from May to June, with Commodore disclosing 9.9% ownership. The activist register shows no 13D filings — all are passive 13G disclosures — so there is no agitator on the cap table, but the density of specialist healthcare funds accumulating shares this year is notable. As a disclosure caveat: all 13D/G stakes are as-last-disclosed and holders dropping below 5% may exit without a further filing.
Insider activity is routine rather than signal-bearing. The CFO, Christopher Ryan Sullivan, executed a series of option exercises and same-day sales in August and September under a pre-arranged 10b5-1 plan — the September trades involved exercising options at $9.88 and selling at market ($16.33), a mechanical compensation transaction that carries no read-through on conviction. The CMO ran similarly structured sales. Net insider activity over 90 days is modestly negative at around -$2 million, but entirely attributable to pre-planned option sales rather than open-market disposals.
The next earnings event falls on November 9. Avalo's recent earnings history has been volatile: the last four prints produced one-day moves of +5.7%, -2.8%, -12.8%, and -4.7%. Three of those four swings were to the downside, and the worst was a 12.8% drawdown followed by an 18% five-day loss in June — the kind of binary outcome that justifies the high short interest in a pre-Phase III name. With abdakibart's clinical calendar and cash runway the central variables, the November print and any interim clinical updates between now and then are what short sellers and long holders will be tracking most closely.
See the live data behind this article on ORTEX.
Open AVTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
